Enlivex Therapeutics initiated with a Buy at EF Hutton

EF Hutton analyst Jason Kolbert initiated coverage of Enlivex Therapeutics with a Buy rating and $13 price target. Enlivex is a cell therapy company “Breaking the Cycle,” interrupting the immune response with off-the-shelf macrophage cell therapy, the analyst tells investors in a research note. The firm says the company’s lead product, Allocetra, is in development to treat osteoarthritis, initially focused on the knee and hand as well as sepsis. EF believes the current clinical data sets show a signal in these indications.